J Clin Oncol 2021 Apr 10
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
Related Questions
Given the importance of minimizing financial toxicity, for patients who have borderline unfavorable intermediate characteristics, is it reasonable to ...
New answer by Radiation Oncologist at National Institutes of Health Clinical Center (November 4, 2024)
Summary: The short answer is that APP4 is unlikely to improve risk prognostication to the extent to which other advanced biomarkers (GC, MMAI, etc.) do. It is also unlikely ei...